Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Diamyd intralymphatic therapy in recent-onset type 1 diabetes with HLA DR3-DQ2
NL-OMON54104Phase 3Recruiting
- Sponsor
- ICON
- Start
- Sep 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Diamyd intralymphatic with Placebo intralymphatic (2 arms). Primary endpoint: Primary endpoint 1. Started Sep 2022; status: recruiting.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON54104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54104.